Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Date

Click to order products descending

Display 30 Products per page

Sivextro
Read More
Sivextro is a second-generation oxazolidinone, while tedizolid phosphate is a prodrug that is cleaved in the bloodstream to the active antibiotic tedizolid. The active moiety tedizolid inhibits bacterial protein synthesis by interacting with the bacterial 23S ribosome initiation complex.
September 10, 2014
Find out more
Vibativ
Read More
Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.
September 10, 2014
Find out more
Aplidin
Read More
Aplidin is an intravenous, marine-originated cyclic depsipeptide antitumor agent. The drug, which is

currently synthesized chemically, was originally isolated from the marine tunicate Aplidium albicans

(Cuadrado et al., 2003; PharmaMar, 2014).
September 4, 2014
Find out more
GLP-1 Pulse Survey

$599.00

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.
August 25, 2014
Find out more
SGLT-2 Pulse Survey

$599.00

We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.
August 25, 2014
Find out more
Post-AAIC KOL Interview

$599.00

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.
August 6, 2014
Find out more
Dyslipidemia KOL Insight Interview #2

$599.00

Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.
July 28, 2014
Find out more
Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data
July 25, 2014
Find out more
Flolan
Read More
In 1995, GlaxoSmithKline’s Flolan (epoprostenol) became the first therapy to be specifically approved for the orphan disease of pulmonary arterial hypertension (PAH).
June 25, 2014
Find out more
Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.
May 13, 2014
Find out more
Breast Cancer KOL Insight Interview

$599.00

Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.
May 8, 2014
Find out more
Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing
May 7, 2014
Find out more
Post-EASL KOL Insight Interview

$599.00

The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
soon-to-be approved, direct-acting antivirals for Hepatitis C.

May 6, 2014
Find out more
Breast Cancer Pulse Survey

$599.00

Drugs and drug candidates discussed:

palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor
April 23, 2014
Find out more
Volasertib
Read More
Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML.
April 22, 2014
Find out more
Midostaurin
Read More
Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.
April 22, 2014
Find out more
Congestive Heart Failure Pulse Survey

$599.00

The study was just closed early, as LCZ696 increased time to first occurrence of either

cardiovascular death or heart failure hospitalization, though details have not been released.

We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

assumptions about what the study found.
April 1, 2014
Find out more
U.S. Ophthalmic Surgical Systems Market, April 2014

$3,750.00

This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.
April 1, 2014
Find out more
Aromatase Resistance and Palbociclib for Breast Cancer

$89.00

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.
April 1, 2014
Find out more
Seizure Pulse Survey

$599.00

Eslicarbazepine has been approved in ex-US markets including the EU for years.

We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.
March 25, 2014
Find out more
NASH KOL Insight Interview #2

$599.00

KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]
March 4, 2014
Find out more
Macitenan for Pulmonary Arterial Hypertension

$89.00

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy
March 1, 2014
Find out more
NASH KOL Insight Interview #1

$599.00

The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
February 20, 2014
Find out more
Palbociclib for Breast Cancer

$89.00

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
February 1, 2014
Find out more
Selexipag for Pulmonary Arterial Hypertension

$89.00

Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.
February 1, 2014
Find out more
Psychiatry KOL Insight Interview

$599.00

At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)
January 24, 2014
Find out more
Spain, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Spain.
November 1, 2013
Find out more
U.S. Markets, Trends, and Opportunities in Patient Monitoring Products

$4,750.00

The intensity and high acuity of the critical care environment, combined with the shortage of experienced registered nurses, means that noninvasive and minimally invasive patient monitoring products will be in great demand during the forecast period covered by this report.
November 1, 2013
Find out more
Germany, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Germany.
October 1, 2013
Find out more
Women’s Health: U.S. Markets for Reproductive Management Products

$3,750.00

This report presents market and competitive analyses for selected leading contraceptive and fertility products as well as an overview of the most common types of contraceptives and fertility drugs/treatments available to women in the United States (U.S.) for reproductive management.

September 2, 2013
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *